London, 9 - 10 March 2027
Schedule
Create your personal agenda –check the favourite icon
Mar 98:59
Conference pass
Welcome Remarks
Keynotes
Chris Shanks, Conference Director, Advanced Therapies, Terrapinn
Mar 99:00
Conference pass
Chair’s Opening Remarks
Keynotes
Ashleigh Furlong, Health reporter, Bloomberg News
Mar 99:05
Conference pass
Fireside Chat: Pioneering a new approach to advanced therapies - Establishing a not-for-profit model for developing a gene therapy
Keynotes
Ilaria Villa, Chief Executive Officer, fondazione telethon
Moderator: Ashleigh Furlong, Health reporter, Bloomberg News
Mar 99:45
Conference pass
Keynote Panel Discussion: From Discovery to Manufacturing – How is AI Transforming Cell & Gene Therapy Development?
Keynotes
Moderator: Miguel Forte, CEO, Kiji Therapeutics and President, International Society of Cell and Gene Therapy, Kiji Therapeutics
Bastiaan Leewis, SVP MSAT, MeiraGTx
Matthieu Coutet, Partner, Sofinnova Partners
Rafiq Hasan, CEO, Complement Therapeutics
Florence Salmon, Global Head Regulatory Cell and Gene Therapies, Roche
Lara Campana, SVP, Head of Research and Translational Science, Resolution Therapeutics
Mar 912:05
Conference pass
Chair’s Remarks: Aline Charpentier, Science Strategy and Innovation Lead, Wellcome Genome Campus
Start-ups Showcase (Track 6)
Aline Charpentier, Science Strategy and Innovation Lead, Wellcome Genome Campus
Mar 912:05
Conference pass
Chair’s Remarks: Carolina Pola, CEO, STAb Therapeutics
Gene Modified Cell Therapy (Track 8)
Carolina Pola, CEO, Stab Therapeutics
Mar 912:05
Conference pass
Chair’s Remarks: Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Supply Chain & Logistics (Track 4)
Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Mar 912:05
Conference pass
Chair’s Remarks: Dimitri Kullmann, Professor of Neurology, UCL Queen Square Institute of Neurology
Gene Therapy (Track 7)
Dimitri Kullmann, Professor of Neurology, University College London (UCL)
Mar 912:05
Conference pass
Chair’s Remarks: Gaik Sui Kee, Director, Vector Development, Orchard Therapeutics
Viral Vector Manufacturing (Track 9)
Gaik Sui Kee, Director, Vector Development, Orchard Therapeutics
Mar 912:05
Conference pass
Chair’s Remarks: James Levine, President, Fondation Ipsen, Ipsen
Innovation (Track 2)
James Levine, President, Fondation Ipsen
Mar 912:05
Conference pass
Chair’s Remarks: Jorg Wischhusen, Professor of Experimental Tumor Immunology, University of Wurzburg School of Medicine
Immunotherapy (Track 5)
Jörg Wischhusen, Professor, Universitätsklinikum Würzburg
Mar 912:05
Conference pass
Chair’s Remarks: Lara Campana, SVP, Research and Translational Science, Resolution Therapeutics
Cell Therapy (Track 3)
Lara Campana, SVP, Head of Research and Translational Science, Resolution Therapeutics
Mar 912:05
Conference pass
Chair’s Remarks: Nicola Redfern, Director, NJ Redfern Ltd.
Evidence, Pricing & Access (Track 1)
Nicola Redfern, Director, NJ Redfern Ltd.
Mar 912:05
Conference pass
Chair's Remarks: David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Cell Therapy Manufacturing (Track 10)
David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Mar 912:10
Conference pass
Are we ready for the age of biotech?
Innovation (Track 2)
James Levine, President, Fondation Ipsen
Mar 912:10
Conference pass
Developing biological reference materials for the cell therapy field
Cell Therapy (Track 3)
Mar 912:10
Conference pass
Developing gene therapy for common forms of epilepsy
Gene Therapy (Track 7)
Dimitri Kullmann, Professor of Neurology, University College London (UCL)
Mar 912:10
Conference pass
Insight from the NHS on apheresis and donor supply: Getting treatments to the patient
Supply Chain & Logistics (Track 4)
Lilian Hook, Director of Cell, Apheresis and Gene Therapies, NHS Blood and Transplant
Mar 912:10
Conference pass
Latest innovations in vector development manufacturing
Viral Vector Manufacturing (Track 9)
Gaik Sui Kee, Director, Vector Development, Orchard Therapeutics
Mar 912:10
Conference pass
Preparing academic projects for commercialisation
Start-ups Showcase (Track 6)
Pamela Tranter, Head, Translational Research Group (TRO), University College London
Mar 912:10
Conference pass
Real world challenges of delivering CAR-T: Harsh realities and future perspectives
Gene Modified Cell Therapy (Track 8)
Mark Lowdell, CSO, INmuneBio
Mar 912:10
Conference pass
Robust manufacturing for replacement cell therapies
Cell Therapy Manufacturing (Track 10)
Kristian Tryggvason, Chief Executive Officer, Alder Therapeutics
Mar 912:10
Conference pass
Targeting and exploiting onco-fetal tolerance mechanisms for cancer and autoimmunity
Immunotherapy (Track 5)
Jörg Wischhusen, Professor, Universitätsklinikum Würzburg
Mar 912:10
Conference pass
Trials and tribulations of actually going through the JCA process
Evidence, Pricing & Access (Track 1)
Sachin Vadgama, Director of HEOR, Multiple Myeloma, Gilead
Mar 912:30
Conference pass
Accelerated downstream process development for viral vectors
Viral Vector Manufacturing (Track 9)
Parag Kumthekar, Lead Gene Therapy Downstream Process Development, UCB
Mar 912:30
Conference pass
AI-powered approach to novel gene therapies
Gene Therapy (Track 7)
Killian Hanlon, CEO, Lir Therapeutics
Mar 912:30
Conference pass
Ex US optionality with an FDA approval: Go/ No go
Evidence, Pricing & Access (Track 1)
Christian Hill, Board Member, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Mar 912:30
Conference pass
Extra corporeal CAR T for safe and accurate dosing
Immunotherapy (Track 5)
David Peritt, Chief Scientific Officer, Lupagen
Mar 912:30
Conference pass
Latest insight on EU policies for ATMP development
Cell Therapy (Track 3)
Giulia Leonetti, Policy Officer, European Commission
Mar 912:30
Conference pass
National academic network proposal for authorization of CAR-T cell production
Gene Modified Cell Therapy (Track 8)
Manel Juan, Immunologist, Hospital Clínic de Barcelona
Mar 912:30
Conference pass
Navigating Cell Therapy Manufacturing: Overcoming Bottlenecks and Creating a Capital-Efficient Path to Scale
Cell Therapy Manufacturing (Track 10)
Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Mar 912:30
Conference pass
Overview of MHRA's Innovation Accelerator for Innovative Products
Innovation (Track 2)
Andrew Zambanini, Head of Innovative Therapies, Innovation Accelerator, MHRA
Mar 912:30
Conference pass
Strategic considerations for designing supply networks for biologics and new modalities
Supply Chain & Logistics (Track 4)
Ulrich Ruemenapp, Senior Biotech Program Lead, Bayer AG
Mar 912:30
Conference pass
The good, bad and the ugly of venture creation
Start-ups Showcase (Track 6)
Aline Charpentier, Science Strategy and Innovation Lead, Wellcome Genome Campus
Mar 912:50
Conference pass
Dual CAR Targeting with CD33 and Tim3 in acute myeloid leukemia
Immunotherapy (Track 5)
Marta Serafini, Associate Professor, School of Medicine and Surgery, University of Milano-Bicocca
Mar 912:50
Conference pass
Leveraging patient experience data to improve outcomes
Evidence, Pricing & Access (Track 1)
Mar 912:50
Conference pass
Stem cell gene therapy for childhood dementias
Gene Modified Cell Therapy (Track 8)
Mar 913:10
Conference pass
Roundtable 10: Pros and cons of setting-up a clinical trial in the UK, Australia and South Korea
Keynotes
Moderator: Emma Ungstrup, Principal Consultant, E J Consulting
Mar 913:10
Conference pass
Roundtable 11: How do we make novel therapies affordable for healthcare systems?
Keynotes
Mar 913:10
Conference pass
Roundtable 12: Commercial ATMP initiatives vs point of care initiatives
Keynotes
Moderator: Angela Borghouts - de Ruijter, Associate Director Market Access, Gilead Sciences
Mar 913:10
Conference pass
Roundtable 13: Future-proofing ATMPs: Navigating the regulatory minefield
Keynotes
Moderator: Amina Al-Mossawi, Qualified Person, AM Consultancy
Mar 913:10
Conference pass
Roundtable 14: Exploring the regulatory challenges for in vivo gene therapies
Keynotes
Moderator: Shirley Bartido, Principal Consultant, CELLiCONsultant
Mar 913:10
Conference pass
Roundtable 2: Tech Transfer from AD to QC: Overcoming pain points and hurdles
Keynotes
Moderator: Rebecca Moore, Director ‑ AD & QC, Quell Therapeutics
Mar 913:10
Conference pass
Roundtable 3: Workforce readiness to support delivery of ATMPs within the NHS
Keynotes
Moderator: Finn Willingham, Northern Alliance Advanced Therapies Treatment Centre Operations Manager, The Newcastle upon Tyne Hospitals NHS Foundation Trust
Moderator: Nisha Shaunak, Trust Head of Programmes, Advanced Therapies, Guy's & St Thomas' NHS Foundation Trust
Mar 913:10
Conference pass
Roundtable 4: Harmonising safety standards for stem cell-based therapies
Keynotes
Moderator: Ivana Barbaric, Professor of Stem Cell Biology, University of Sheffield
Mar 913:10
Conference pass
Roundtable 5: Future-proofing cell therapies: Strategic lifecycle and comparability planning
Keynotes
Moderator: Alison Caldwell, Manager, CMC Regulatory Affairs, Resolution Therapeutics
Mar 913:10
Conference pass
Roundtable 6: Designing ATMP processes with the end in mind - What should we fix early and what should we leave flexible?
Keynotes
Moderator: Marsela Qesari, CMC Manager, fondazione telethon
Mar 913:10
Conference pass
Roundtable 7: Exploring board-room effectiveness in biotech
Keynotes
Moderator: Dominic Schmidt, General Partner, Advent Life Sciences
Moderator: Rachel Abbott, Chief Executive Officer, Pan Cancer T
Mar 913:10
Conference pass
Roundtable 8: Exploring the safety considerations of CRISPR technology and different approaches to epigenetic editing
Keynotes
Moderator: Anna-Lina Cavallo, Director Discovery Cell and Gene Therapy integrated Bioanalysis, Astrazeneca
Moderator: Claudio Mussolino, Group Leader - Genome and Epigenome Engineering, Freiburg University Medical Center
Mar 913:10
Conference pass
Roundtable 9: LVV vs AAV: Key considerations on which approach to take?
Keynotes
Moderator: Claudiu Cozmescu, Postdoctoral Researcher, Gissen Lab, University College London
Mar 914:10
Conference pass
Chair’s Remarks: Arsalan Wafi, Academic Clinical Lecturer, King's College London
Cell Therapy Manufacturing (Track 10)
Arsalan Wafi, Academic Clinical Lecturer in Vascular Surgery, King's College London
Mar 914:10
Conference pass
Chair’s Remarks: Jaap Boelens, Chief Stem Cell Transplantation & Cellular Therapies Pediatrics, Memorial Sloan Kettering Cancer Center
Gene Therapy (Track 7)
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Mar 914:10
Conference pass
Chair’s Remarks: Leila Abbas, Preclinical Lead, Rinri Therapeutics
Innovation (Track 2)
Leila Abbas, Pre Clinical Lead, Rinri Therapeutics
Mar 914:10
Conference pass
Chair’s Remarks: Mohamed Awwad, Group Leader, Heidelberg University Hospital
Immunotherapy (Track 5)
Mohamed Awwad, Group Leader, Heidelberg University Hospital
Mar 914:10
Conference pass
Chair’s Remarks: Nicola Ambler, Co-Founder, The CGT Circle
Start-ups Showcase (Track 6)
Nicola Ambler, Founder, The CGT Circle
Mar 914:10
Conference pass
Chair’s Remarks: Patrick Hopkinson, Independent HTA Expert
Cell Therapy (Track 3)
Mar 914:10
Conference pass
Chair’s Remarks: Pilar Redondo, Site Head Madrid, Cell Therapy Technology Center, Takeda
Supply Chain & Logistics (Track 4)
Pilar Redondo, Site Head Madrid, Cell Therapy Technology Center, Takeda
Mar 914:10
Conference pass
Chair’s Remarks: Raphaël G. Ognar, CEO & Co-Founder, NKILT Therapeutics Inc
Gene Modified Cell Therapy (Track 8)
Raphael Ognar, President & CEO, Co-founder, NKILT Therapeutics Inc.
Mar 914:10
Conference pass
Chair’s Remarks: Simon Howell, Professor, KCL
Viral Vector Manufacturing (Track 9)
Simon Howell, Professor, KCL
Mar 914:10
Conference pass
Chair's Remarks: Christian Hill, Board Member, European Confederation of Pharmaceutical Entrepreneurs
Evidence, Pricing & Access (Track 1)
Christian Hill, Board Member, European Confederation of Pharmaceutical Entrepreneurs (Belgium)
Mar 914:15
Conference pass
Breaking new barriers in neuroscience: Translational gene therapy for prevalent indications
Gene Therapy (Track 7)
Mar 914:15
Conference pass
Building an inclusive culture in biotech
Start-ups Showcase (Track 6)
Nicola Ambler, Founder, The CGT Circle
Mar 914:15
Conference pass
Cell therapy for neonatal brain injury
Cell Therapy (Track 3)
Mar 914:15
Conference pass
Engineering the biology of AAV secretion with MAAP
Viral Vector Manufacturing (Track 9)
Darren Nesbeth, Associate Professor, University College London
Mar 914:15
Conference pass
First in human trial for solid tumour in India
Gene Modified Cell Therapy (Track 8)
Dinesh Kundu, CEO, East Ocyon Bio Pvt. Ltd.
Mar 914:15
Conference pass
Igniting childhood cancer gene therapy: Delivering impact for children
Immunotherapy (Track 5)
Aleck Jones, CEO, Co-founder, Kindling Bio
Mar 914:15
Conference pass
Scalability connection between manufacturing and QC
Cell Therapy Manufacturing (Track 10)
Christopher Ballas, Global Commercial Lead, Custom Cell Products, Cook MyoSite Inc
Mar 914:15
Conference pass
Solving the EV Consistency Challenge: Enabling mass adoption through a platform approach
Innovation (Track 2)
David Kuntin, CEO, Mesenbio
Mar 914:15
Conference pass
Supporting commercialisation through operational and supply chain strategies
Supply Chain & Logistics (Track 4)
Ben Weil, Chief Operating Officer & Chief Manufacturing Officer, INmuneBio
Mar 914:15
Conference pass
The case for launching advanced therapies in RoW markets: Exploring challenges and opportunities
Evidence, Pricing & Access (Track 1)
Pedro Borga, Global Pricing Director, BioMarin Pharmaceutical Inc.
Mar 914:15
Conference pass
Unlocking the potential of disease prevention through regulatory science
Innovation (Track 2)
Mar 914:35
Conference pass
A NICE Lesson from the Frontline of a Gene Therapy Evaluation
Evidence, Pricing & Access (Track 1)
Sheela Upadhyaya, Rare Disease Consultant, Rarely Ordinary
Mar 914:35
Conference pass
Gene therapy for kidney disease
Gene Therapy (Track 7)
Mar 914:35
Conference pass
Multi-pathway armouring of CAR-T cells
Gene Modified Cell Therapy (Track 8)
Vlad Seitan, Chief Scientific Officer, Laverock Therapeutics
Mar 914:35
Conference pass
Mar 914:55
Conference pass
Challenges of manufacturing in an academic hospital
Cell Therapy Manufacturing (Track 10)
Alessandra Magnani, Head of the advanced therapies and immunotherapy platform, Hospital Sant Joan de Déu Barcelona
Mar 914:55
Conference pass
Developing your QC strategy for early and late phase development
Supply Chain & Logistics (Track 4)
Lindsay Davies, CSO, NextCell Pharma and CEO, QVance, NextCell Pharma
Mar 914:55
Conference pass
Exploring the differences between extrapolation and real-world outcomes
Evidence, Pricing & Access (Track 1)
Angela Borghouts - de Ruijter, Associate Director Market Access, Gilead Sciences
Mar 914:55
Conference pass
From start-up to a publicly traded company
Start-ups Showcase (Track 6)
Mar 914:55
Conference pass
Immune engagement through oncolytic peptides
Immunotherapy (Track 5)
Mark Eccleston, CEO, ValiRx
Mar 914:55
Conference pass
Lessons learned from spinning out in gene therapy
Gene Therapy (Track 7)
Rafiq Hasan, CEO, Complement Therapeutics
Mar 914:55
Conference pass
NK-derived vesicles for cancer therapy
Cell Therapy (Track 3)
Marit Inngjerdingen, Professor, University of Oslo
Mar 914:55
Conference pass
Operational considerations for the delivery of CAR-T
Gene Modified Cell Therapy (Track 8)
Keith Wilson, Director, South Wales Blood and Marrow Transplant Programme, Cardiff and Vale University Health Board
Mar 914:55
Conference pass
Pharmacy: The hidden backbone of delivering advanced therapies
Innovation (Track 2)
Tanya Patel, Senior Manager CTSM, BioNTech
Mar 914:55
Conference pass
Potency assay development strategy for cell & gene therapies
Viral Vector Manufacturing (Track 9)
Simon Briggs, Director Advanced Analytics, Orchard Therapeutics Ltd
Mar 914:55
Conference pass
Standardisation of TIL-ACT manufacturing
Cell Therapy Manufacturing (Track 10)
Jara Palomero, Qualified Person, VHIO - Vall d'Hebron Institute of Oncology
Mar 915:15
Conference pass
Antibody Fc engineering for cancer immunotherapy
Immunotherapy (Track 5)
Mar 915:15
Conference pass
Engineering capsids for lower human antibody interaction
Innovation (Track 2)
Adrian Westhaus, Researcher, Genethon
Mar 915:15
Conference pass
Future impact of cell and gene therapies - horizon scanning for the NHS
Cell Therapy (Track 3)
Sheena Vithlani, Medicines Advice Advanced Pharmacist, NHS SPS Medicines Advice & Horizon Scanning Service
Nicola Bradley, Senior Medicines Advice Pharmacist – Horizon scann, NHS SPS Medicines Advice & Horizon Scanning Service
Mar 915:15
Conference pass
Latest update on ATMP-NL: Accelerating access to advanced therapies
Evidence, Pricing & Access (Track 1)
Mike Broeders, Advisor, FAST (Future Affordable Sustainable Therapies)
Mar 915:15
Conference pass
Next-generation immune redirection strategies for solid and haematological tumors
Gene Modified Cell Therapy (Track 8)
Carolina Pola, CEO, Stab Therapeutics
Mar 915:15
Conference pass
Stem cell gene therapy in metabolic disease: Current status and overcoming barriers to future implementation
Gene Therapy (Track 7)
Robert Wynn, Consultant Paediatric Haematologist & Director of Paediatric Bone Marrow Transplant Programme, Manchester University NHS Foundation Trust
Mar 915:35
Conference pass
Access and evidence considerations for ATMPs in Wales
Evidence, Pricing & Access (Track 1)
Hannah Crocker, Advanced Therapies Outcomes Manager, NHS Wales Joint Commissioning Committee (NWJCC)
Mar 915:35
Conference pass
Active learning strategies to optimise AAV manufacturing
Viral Vector Manufacturing (Track 9)
Hugh O'Brien, Founder, Lir Therapeutics
Mar 915:35
Conference pass
Autologous cell therapy manufacturing processes: From manufacturing to bedside
Cell Therapy Manufacturing (Track 10)
Arsalan Wafi, Academic Clinical Lecturer in Vascular Surgery, King's College London
Mar 915:35
Conference pass
Challenges of human heritable gene editing
Gene Modified Cell Therapy (Track 8)
Miguel Forte, CEO, Kiji Therapeutics and President, International Society of Cell and Gene Therapy, Kiji Therapeutics
Mar 915:35
Conference pass
Development of iPSC derived CAR-NK Cells for Immunotherapy
Cell Therapy (Track 3)
Marina Tarunina, Research Director, Plasticell
Mar 915:35
Conference pass
Epigenetic novel approaches for immunotherapy
Immunotherapy (Track 5)
Mohamed Awwad, Group Leader, Heidelberg University Hospital
Mar 915:35
Conference pass
It’s not all grim up North: Opportunities outside the ‘Golden Triangle’
Innovation (Track 2)
Leila Abbas, Pre Clinical Lead, Rinri Therapeutics
Mar 915:35
Conference pass
Organoid technology applications for gene therapy development
Gene Therapy (Track 7)
Amelia Lane, Director Preclinical Development, MeiraGTx
Mar 915:35
Conference pass
Panel Discussion: Considerations for Best Practice in Supply Chain and Logistics for Advanced Therapies
Supply Chain & Logistics (Track 4)
Moderator: Diana Hernandez, Director of Immune and Advanced Therapies, Anthony Nolan
Lilian Hook, Director of Cell, Apheresis and Gene Therapies, NHS Blood and Transplant
Mark Lowdell, CSO, INmuneBio
Christopher Ballas, Global Commercial Lead, Custom Cell Products, Cook MyoSite Inc
Ulrich Ruemenapp, Senior Biotech Program Lead, Bayer AG
Sarah Snykers, Head of Site Strategy and Excellence, Legend Biotech
Lindsay Davies, CSO, NextCell Pharma and CEO, QVance, NextCell Pharma
Mar 915:55
Conference pass
Bispecific therapeutics for oncology and autoimmune disease
Immunotherapy (Track 5)
Sarah Leonard, Interim Chief Executive Officer, T-Cypher Bio
Mar 915:55
Conference pass
CAR-T for autoimmune neurological conditions
Gene Modified Cell Therapy (Track 8)
Frederick Vonberg, Consultant Neurologist, University College London Hospitals NHS Foundation Trust
Mar 915:55
Conference pass
From bench to beside: Practical considerations for commercialisation
Start-ups Showcase (Track 6)
Ashish Patel, Reader in Vascular Surgery & Sciences, King's College London / Guy's & St Thomas' NHS Foundation Trust
Mar 915:55
Conference pass
Positioning patient centred outcomes as endpoints for ATMP development
Evidence, Pricing & Access (Track 1)
Devin Peipert, Professor of Health Outcomes Measurement, University of Birmingham
Mar 916:45
Conference pass
Chair’s Remarks: Ali Roghanian, Professor in Cancer Immunotherapy, University of Southampton
Gene Modified Cell Therapy (Track 8)
Ali Roghanian, Professor in Cancer Immunotherapy, University of Southampton
Mar 916:45
Conference pass
Chair’s Remarks: Heather Main, Co-Founder, Hoya Consulting
Evidence, Pricing & Access (Track 1)
Heather Main, Co-Founder, Hoya Consulting
Mar 916:45
Conference pass
Chair’s Remarks: Hugh JM Brady, Professor of Immunology, Imperial College London & CSO, NK:IO Ltd
Immunotherapy (Track 5)
Hugh JM Brady, Professor of Immunology, Imperial College London
Mar 916:45
Conference pass
Chair’s Remarks: Katherine Forsey, CRO, Charcot-Marie-Tooth Association
Innovation (Track 2)
Mar 916:45
Conference pass
Chair’s Remarks: Rahul Khetan, Venture Associate, UCB
Start-ups Showcase (Track 6)
Mar 916:45
Conference pass
Chair’s Remarks: Ricardo Silva, Principal Scientist, iBET
Viral Vector Manufacturing (Track 9)
Ricardo Silva, Senior Scientist, iBET: Instituto de Biologia Experimental e Tecnológica
Mar 916:45
Conference pass
Chair’s Remarks: Samantha Barber, CEO, Gene People
Gene Therapy (Track 7)
Samantha Barber, Chief Executive Officer, Gene People
Mar 916:45
Conference pass
Chair’s Remarks: Sven Kili, Partner, Saisei Ventures
Cell Therapy (Track 3)
Sven Kili, Partner, Saisei Ventures
Mar 916:45
Conference pass
Chair’s Remarks: Tamás Laufer, Researcher, UCL/Orchard Therapeutics
Manufacturing 4.0 (Track 4)
Mar 916:45
Conference pass
Chair's Remarks: Ashish Patel, Reader in Vascular Surgery & Sciences, King's College London / Guy's & St Thomas' NHS Foundation Trust
Cell Therapy Manufacturing (Track 10)
Ashish Patel, Reader in Vascular Surgery & Sciences, King's College London / Guy's & St Thomas' NHS Foundation Trust
Mar 916:50
Conference pass
Approaches to innate immunotherapy
Immunotherapy (Track 5)
Hugh JM Brady, Professor of Immunology, Imperial College London
Mar 916:50
Conference pass
Clinical update on the development of Glycostem’s NK cell product Inaleucel
Cell Therapy (Track 3)
Jan Spanholtz, Chief Scientific Officer, Glycostem Therapeutics
Mar 916:50
Conference pass
Developing next generation gene regulation technologies
Start-ups Showcase (Track 6)
Mark Isalan, Professor of Engineering Biology, Imperial College London/ Toggle Therapeutics
Mar 916:50
Conference pass
Establishing distributed RNA bio foundries
Manufacturing 4.0 (Track 4)
Mar 916:50
Conference pass
Globalising gene therapies: From inaccessibility to standard of care
Gene Therapy (Track 7)
Cem Zorlular, CEO, Er-Kim Pharmaceuticals
Mar 916:50
Conference pass
Lessons learned and new perspectives in the development of innovative cell therapy
Gene Modified Cell Therapy (Track 8)
Raphael Ognar, President & CEO, Co-founder, NKILT Therapeutics Inc.
Mar 916:50
Conference pass
Process development for virus-based therapies
Viral Vector Manufacturing (Track 9)
Ricardo Silva, Senior Scientist, iBET: Instituto de Biologia Experimental e Tecnológica
Mar 916:50
Conference pass
Selection and quality oversight of contract testing laboratories
Cell Therapy Manufacturing (Track 10)
Anna-Kaisa Lehtivarjo, VP Quality Assurance, Resolution Therapeutics Ltd
Mar 916:50
Conference pass
Trends in access barriers for advanced therapies in the UK
Evidence, Pricing & Access (Track 1)
Brad Groves, Director, NICE Advice, National Institute for Health & Care Excellence (NICE)
Mar 916:50
Conference pass
Unlocking the power of success through scientific collaboration
Innovation (Track 2)
Mo Girach, Honorary Fellow, University of Buckingham
Mar 917:10
Conference pass
Assay development for infectious titer
Viral Vector Manufacturing (Track 9)
Giuliana Minani Bertolino, Senior MSAT scientist, GTVF King’s College London
Mar 917:10
Conference pass
Delivering scalable manufacturing with quality in mind
Manufacturing 4.0 (Track 4)
Peter Andersen, Chief Research & Development Officer, TREEFROG THERAPEUTICS
Mar 917:10
Conference pass
Dendritic cell therapy for solid tumours
Immunotherapy (Track 5)
Mar 917:10
Conference pass
Digitalisation and automation for the manufacturing of advance therapies
Cell Therapy Manufacturing (Track 10)
Anna Louisa Weltin, Research Fellow, Fraunhofer IPT
Mar 917:10
Conference pass
Engineering next generation T-cells for cancer immunotherapy
Gene Modified Cell Therapy (Track 8)
Mar 917:10
Conference pass
How to find a treatment for an ultra-rare disease
Evidence, Pricing & Access (Track 1)
Jonathan Bracey, Founder, MVA Society
Mar 917:10
Conference pass
Real world experiences for cell collection in ex vivo gene therapy
Gene Therapy (Track 7)
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Mar 917:10
Conference pass
Treating 1 in 2500: Delivering treatments to the peripheral nervous system
Innovation (Track 2)
Mar 917:10
Conference pass
Understanding mechanism of action for a smooth regulatory process
Cell Therapy (Track 3)
Kayleigh Thirlwell, Sr Director, Resolution Therapeutics
Mar 917:10
Conference pass
What can AI do for biopharma beyond drug discovery?
Start-ups Showcase (Track 6)
Ilya Yasny, Partner, LanceBio Ventures
Mar 917:30
Conference pass
Panel Discussion: Emerging Trends and Opportunities in Gene Therapy Development
Gene Therapy (Track 7)
Moderator: Samantha Barber, Chief Executive Officer, Gene People
David Kuntin, CEO, Mesenbio
Mary Wang, Director, Patient Engagement, Genespire
Devin Peipert, Professor of Health Outcomes Measurement, University of Birmingham
Azadeh Kia, VP Gene Therapy Research, Beacon Therapeutics
Jaap Jan Boelens, Chief, Transplantation and Cellular Therapies, Memorial Sloan-Kettering Cancer Center
Mar 917:30
Conference pass
Panel Discussion: Exploring Next Generation Gene Editing Platforms for Cell & Gene Therapies
Gene Modified Cell Therapy (Track 8)
Moderator: Randolph Corteling, Chief Scientific Officer, ReNeuron
Steffen Goletz, Professor, Department of Biotechnology and Biomedicine, Danish Technical University
Laurie Menger, Advanced T-cell Therapy group leader, Gustave Roussy/INSERM
Vlad Seitan, Chief Scientific Officer, Laverock Therapeutics
Roberto Nitsch, Director, AstraZeneca
Cecile BAUCHE, CSO, Alaya.bio
Mar 917:30
Conference pass
Panel Discussion: Exploring Next Generation Viral Vectors and Emerging Vector Delivery Systems
Viral Vector Manufacturing (Track 9)
Moderator: Antonio Roldao, Head of Cell-based Vaccines Development Lab, IBET
Darren Nesbeth, Associate Professor, University College London
Parag Kumthekar, Lead Gene Therapy Downstream Process Development, UCB
Simon Briggs, Director Advanced Analytics, Orchard Therapeutics Ltd
Simon Walker, Head of MSAT, GTVF, King's College London
Mar 917:30
Conference pass
Panel Discussion: Innovative approaches to therapeutic immune cells: CAR-T and beyond
Immunotherapy (Track 5)
Moderator: Raphael Ognar, President & CEO, Co-founder, NKILT Therapeutics Inc.
Dinesh Kundu, CEO, East Ocyon Bio Pvt. Ltd.
Mark Eccleston, CEO, ValiRx
Anton Van der Merwe, Professor of Molecular Immunology, University of Oxford
Mar 917:30
Conference pass
Panel Discussion: Manufacturing 4.0: Harnessing innovation to achieve smarter, more efficient and sustainable manufacturing
Manufacturing 4.0 (Track 4)
Moderator: Matthew Cobb, Independent Consultant, Hoya Consulting
Jan Spanholtz, Chief Scientific Officer, Glycostem Therapeutics
Eleuterio Lombardo, Former Director of Cell Therapy Characterization & Development, Cell Therapies, Takeda
Ben Weil, Chief Operating Officer & Chief Manufacturing Officer, INmuneBio
Peter Andersen, Chief Research & Development Officer, TREEFROG THERAPEUTICS
Mar 917:30
Conference pass
Panel Discussion: Navigating The Complex Journey of Cell Therapy Manufacturing: Overcoming the Bottlenecks and Scaling-Up
Cell Therapy Manufacturing (Track 10)
Moderator: Lara Campana, SVP, Head of Research and Translational Science, Resolution Therapeutics
Tara Sadeghi, Chief Operating Officer, Cellenkos Inc.
Manel Juan, Immunologist, Hospital Clínic de Barcelona
Ketki Vispute, Associate Director, CMC, MSAT, Autolus Ltd
Tatyana Matveeva, Director of cGMP Operations, Mass General Hospital
Mar 917:30
Conference pass
Panel Discussion: Overcoming Barriers and Expanding Access to Cell and Gene Therapies
Evidence, Pricing & Access (Track 1)
Dilip Patel, SVP Global Pricing and Market Access, Autolus
Henriette Burghoorn, Associate Director, Market Access, Gilead Sciences
Roger Legtenberg, Co-Founder & Managing Partner, Partners4Patients Foundation
Hannah Crocker, Advanced Therapies Outcomes Manager, NHS Wales Joint Commissioning Committee (NWJCC)
Mike Broeders, Advisor, FAST (Future Affordable Sustainable Therapies)
Angela Borghouts - de Ruijter, Associate Director Market Access, Gilead Sciences
Mar 917:30
Conference pass
Panel Discussion: Surviving The Valley of Death: How Can Young Companies Succeed?
Start-ups Showcase (Track 6)
Carolina Pola, CEO, Stab Therapeutics
Sarah Leonard, Interim Chief Executive Officer, T-Cypher Bio
Claudia Andretta, Strategic Advisor, Sichem Bio
Kiren Baines-Mortimore, CEO and Co-Founder, Valaya Bio
Semra Kitchen, Senior Director, Search & Evaluation, R&I, Astrazeneca
Mar 917:30
Conference pass
Panel Discussion: When’s the right time to start planning for commercial launch?
Cell Therapy (Track 3)
Moderator: Sven Kili, Partner, Saisei Ventures
Marit Inngjerdingen, Professor, University of Oslo
Piotr Trzonkowski, CEO, PolTREG
Sean Russell, Head of Regulatory Affairs, Telethon Foundation
Chris Williams, Chief Business Officer, Autolus
Mar 917:30
Conference pass
Panel Discussion: Where’s the Money? Evolution And Future Outlook for Investment in Advanced Therapies
Innovation (Track 2)
Moderator: Elena Beltrami, Investment Manager, Indaco Biotech Fund
Cem Zorlular, CEO, Er-Kim Pharmaceuticals
Pedro Correa de Sampaio, CEO, Neobe Therapeutics
Giovanni Rizzo, Partner Biotech Fund, Indaco Venture Partners
Luke Henry, Chief Business Officer, Quell Therapeutics
Robert Balfour, Investment Director, Alsa Ventures
Create your personal agenda –check the favourite icon
Mar 109:00
Conference pass
Chair’s Opening Remarks
Keynotes
Catherine Burns, BBC Health Correspondent, BBC News
Mar 109:05
Conference pass
Latest update from the MHRA on the regulatory framework for advanced therapies
Keynotes
Jacob George, Chief Medical and Scientific Officer, MHRA
Mar 109:45
Conference pass
Fireside Chat: Navigating the landscape for gene therapies to achieve commercialisation
Keynotes
Moderator: Andrew Joseph, Europe Correspondent, STAT
Mar 1011:55
Conference pass
Chair’s Remarks: Anne Rosser, Professor of Clinical Neurosciences, Cardiff University
Cell Therapy (Track 3)
Anne Rosser, Professor of Clinical Neurosciences, Cardiff University
Mar 1011:55
Conference pass
Chair’s Remarks: Bernd Giebel, Professor, University Hospital Essen
Gene Editing (Track 5)
Bernd Giebel, Professor, University Hospital Essen
Mar 1011:55
Conference pass
Chair’s Remarks: Claudia Andretta, Strategic Advisor, Sichem Bio
Start-ups Showcase (Track 6)
Claudia Andretta, Strategic Advisor, Sichem Bio
Mar 1011:55
Conference pass
Chair’s Remarks: David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Regulation (Track 1)
David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Mar 1011:55
Conference pass
Chair’s Remarks: Ilves Sanna, Head of Pharmacy Clinical Trials & Aseptic Services, The Royal Marsden NHS Foundation Trust
Pre-Clinical & Clinical (Track 4)
Ilves Sanna, Head of Pharmacy Clinical Trials & Aseptic Services, The Royal Marsden NHS Foundation Trust
Mar 1011:55
Conference pass
Chair’s Remarks: Jon Amund Kyte, Head of Department for Clinical Cancer Research, University of Oslo, Oslo University Hospital
Gene Modified Cell Therapy (Track 8)
Mar 1011:55
Conference pass
Chair’s Remarks: Manal Mohammed, Associate Professor, University of Westminster
Innovation (Track 2)
Manal Mohammed, Associate Professor, University of Westminster
Mar 1011:55
Conference pass
Chair’s Remarks: Rajvinder Karda, Professor in Gene Therapy, Institute for Women’s Health, University College London
Gene Therapy (Track 7)
Rajvinder Karda, Professor in Gene Therapy, Institute for Women’s Health, University College London
Mar 1011:55
Conference pass
Chair’s Remarks: Sara Nolbrant, Director, Pre-GMP Facility, Lund Stem Cell Center
Cell Therapy Manufacturing (Track 10)
Sara Nolbrant, Director, Pre-GMP Facility, Lund Stem Cell Center
Mar 1011:55
Conference pass
Chair’s Remarks: Toby Gamlen, Head of Manufacturing, Gene Therapy Innovation and Manufacturing Centre, University of Sheffield
Viral Vector Manufacturing (Track 9)
Toby Gamlen, Head of Manufacturing, Gene Therapy Innovation and Manufacturing Centre, University of Sheffield
Mar 1012:00
Conference pass
Accelerating the development of cell therapies through pre-GMP infrastructure
Cell Therapy Manufacturing (Track 10)
Sara Nolbrant, Director, Pre-GMP Facility, Lund Stem Cell Center
Mar 1012:00
Conference pass
Democratisation of whole genome sequencing at a population scale: Implications for precision medicine
Innovation (Track 2)
Mar 1012:00
Conference pass
Developing a cell therapy for Huntington’s disease
Cell Therapy (Track 3)
Anne Rosser, Professor of Clinical Neurosciences, Cardiff University
Mar 1012:00
Conference pass
Developing better solid tumour targeting by allogenic gamma delta T cell therapy through biomimetic modelling
Gene Modified Cell Therapy (Track 8)
Daniel Fowler, Research Fellow, UCL
Mar 1012:00
Conference pass
Developing next generation medicines: Delivering a gene therapy for common indications
Gene Therapy (Track 7)
Mustafa Munye, VP Operations, Complement Therapeutics
Mar 1012:00
Conference pass
Exosomes for targeted drug delivery: Unlocking the potential of gene editing complexes
Gene Editing (Track 5)
Samantha Thomas, Head of Research, ReNeuron
Mar 1012:00
Conference pass
Getting in early: Realising the value of regulatory engagement
Regulation (Track 1)
Mar 1012:00
Conference pass
Leveraging platforms to support suspension process for LVV manufacturing
Viral Vector Manufacturing (Track 9)
Chrysanthi Sitmalidou, Senior Scientist, Orchard Therapeutics
Mar 1012:00
Conference pass
Optimising the antigen sensitivity of immunotherapies by engineering matched extracellular sizes
Start-ups Showcase (Track 6)
Omer Dushek, Professor of Molecular Immunology, University of Oxford
Mar 1012:00
Conference pass
Vaccine innovation pathway: Delivering treatment to patients outside the hospital
Pre-Clinical & Clinical (Track 4)
Ilves Sanna, Head of Pharmacy Clinical Trials & Aseptic Services, The Royal Marsden NHS Foundation Trust
Mar 1012:20
Conference pass
Developing an ocular gene therapy for CLN2 Batten’s disease
Gene Therapy (Track 7)
Robert Henderson, Honorary Associate Professor, UCL GOS Institute of Child Health
Mar 1012:20
Conference pass
Engineered bacteria to enhance cell therapy responses
Gene Modified Cell Therapy (Track 8)
Pedro Correa de Sampaio, CEO, Neobe Therapeutics
Mar 1012:20
Conference pass
High-resolution quality control in new cells and tissues using single-cell and spatial transcriptomics
Innovation (Track 2)
Mar 1012:20
Conference pass
In vivo gene editing for rare disease treatment
Gene Editing (Track 5)
Marcello Maresca, Senior Director, Genome Engineering Team, AstraZeneca
Mar 1012:20
Conference pass
Overview of clinical trials in Thailand
Pre-Clinical & Clinical (Track 4)
Chaiyong Koaykul, Lecturer, Faculty of Medicine, Chulalongkorn University-Excellence Center For Advanced Therapy Medicinal Products
Mar 1012:20
Conference pass
Use of CAR-T regs for the treatment of rheumatoid diseases
Cell Therapy (Track 3)
Marc Martinez-Llordella, Founder and VP Biology, Quell Therapeutics
Mar 1012:40
Conference pass
Accelerating clinical trials set-up and delivery
Pre-Clinical & Clinical (Track 4)
Beatriz Duran, Consultant Pharmacist and Head of Clinical Trials Pharmacy Service and ATMPs, Manchester University NHS Foundation Trust
Mar 1012:40
Conference pass
CAR-T therapy targeting solid cancers
Gene Modified Cell Therapy (Track 8)
Mar 1012:40
Conference pass
Creating operational efficiency in flow cytometry workflows
Cell Therapy Manufacturing (Track 10)
Padraig Donlon, Analytical Development Research Scientist, Autolus
Mar 1012:40
Conference pass
Developing a bacteriophage therapy
Innovation (Track 2)
Manal Mohammed, Associate Professor, University of Westminster
Mar 1012:40
Conference pass
From bench to clinic: Unlocking the power of data modelling for accelerating cell therapies
Cell Therapy (Track 3)
Jose Meseguer Ripolles, Head, Translational Digital and Data Science, Resolution Therapeutics
Mar 1012:40
Conference pass
Lentiviral vector manufacturing and quality aspects in a GMP academic facility
Viral Vector Manufacturing (Track 9)
Mar 1012:40
Conference pass
Novel gene therapies for incurable inherited childhood epilepsy
Gene Therapy (Track 7)
Rajvinder Karda, Professor in Gene Therapy, Institute for Women’s Health, University College London
Mar 1012:40
Conference pass
Novel platform of glycoengineered sEV for superior drug delivery and gene therapy
Gene Editing (Track 5)
Steffen Goletz, Professor, Department of Biotechnology and Biomedicine, Danish Technical University
Mar 1012:40
Conference pass
Regulatory Approval & Quality Assessment of ATMPs
Regulation (Track 1)
Mar 1012:40
Conference pass
Specialist viral vector manufacturing in Northern England: Opportunities and regional challenges
Viral Vector Manufacturing (Track 9)
Toby Gamlen, Head of Manufacturing, Gene Therapy Innovation and Manufacturing Centre, University of Sheffield
Mar 1013:00
Conference pass
Challenges and strategies for the development of bicistronic AAV gene therapies for retinal disorders
Gene Therapy (Track 7)
Christopher Benwell, Assistant Director of Technical Analytics, ikarovec
Mar 1013:00
Conference pass
Error-free genome editing for eradication of life-threatening persistent virus infections
Gene Editing (Track 5)
Mar 1013:00
Conference pass
How pharmacy guidance is standardising ATMP implementation for marketed & investigational medicines
Regulation (Track 1)
Anne Black, Regional QA Specialist Pharmacist and Qualified Person, NHS Specialist Pharmacy Service
Mar 1013:00
Conference pass
IMANs:Neutrophil based cell therapy for cancer and beyond
Cell Therapy (Track 3)
Mar 1013:00
Conference pass
Innovating new antibody drug conjugate strategies
Innovation (Track 2)
Marc de la Roche, Asst. Professor, Dept. of Biochemistry, University of Cambridge
Mar 1013:00
Conference pass
Navigating the complex regulatory and compliance requirements for GMP sites
Cell Therapy Manufacturing (Track 10)
Tatyana Matveeva, Director of cGMP Operations, Mass General Hospital
Mar 1013:00
Conference pass
Regulatory T cell therapies in transplantation
Pre-Clinical & Clinical (Track 4)
Fadi Issa, Professor of Transplantation, University of Oxford
Mar 1013:00
Conference pass
Reprogrammable gene therapy for neuroblastoma
Gene Modified Cell Therapy (Track 8)
Tina Karapouliou, Research Fellow, UCL GOS ICH
Mar 1014:20
Conference pass
Chair’s Remarks: Alejandro Madrigal, Professor of Haematology, UCL Cancer Institute
Gene Modified Cell Therapy (Track 8)
Alejandro Madrigal, OBE FMedSci, Professor of Haematology, UCL Cancer Institute
Mar 1014:20
Conference pass
Chair’s Remarks: Andrew Roddam, Founder & Principal, Cibola Life Sciences Ltd
Regulation (Track 1)
Andrew Roddam, Founder & Principal, Cibola Life Sciences Ltd
Mar 1014:20
Conference pass
Chair’s Remarks: Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies, Programme Director, Translational Skills, LifeArc
Gene Therapy (Track 7)
Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Programme Director, Translational Skills, LifeArc
Mar 1014:20
Conference pass
Chair’s Remarks: Beatriz Duran, Consultant Pharmacist and Head of Clinical Trials Pharmacy Service and ATMPs, Manchester University NHS Foundation Trust
Pre-Clinical & Clinical (Track 4)
Beatriz Duran, Consultant Pharmacist and Head of Clinical Trials Pharmacy Service and ATMPs, Manchester University NHS Foundation Trust
Mar 1014:20
Conference pass
Chair’s Remarks: Elsa Abranches, Chief Scientific Officer, ViSync Technologies
Viral Vector Manufacturing (Track 9)
Mar 1014:20
Conference pass
Chair’s Remarks: Giorgia Santilli, Associate Professor in Gene Therapy, UCL Great Ormond Street Institute of Child Health
Gene Editing (Track 5)
Giorgia Santilli, Associate Professor in Gene Therapy, UCL Great Ormond Street Institute of Child Health
Mar 1014:20
Conference pass
Chair’s Remarks: Katie Binley, Chief Scientific Officer, ikarovec
Start-ups Showcase (Track 6)
Katie Binley, Chief Scientific Officer, ikarovec
Mar 1014:20
Conference pass
Chair’s Remarks: Owen Bain, Director/Qualified Person, Cell & Vector Innovation Centre, Royal Free London NHS Foundation Trust
Cell Therapy Manufacturing (Track 10)
Owen Bain, Director/Qualified Person, Cell & Vector Innovation Centre, Royal Free London NHS Foundation Trust
Mar 1014:20
Conference pass
Chair’s Remarks: Ricardo Baptista CTO, SmartCella
Innovation (Track 2)
Ricardo Baptista, Chief Technology Officer, SmartCella
Mar 1014:20
Conference pass
Chair’s Remarks: Salah Mansour, Professor, University of Southampton
Cell Therapy (Track 3)
Salah Mansour, Professor, University of Southampton
Mar 1014:25
Conference pass
Advanced cell imaging across sectors
Pre-Clinical & Clinical (Track 4)
Davide Danovi, Independent Partner, Hoya Consulting
Mar 1014:25
Conference pass
CAR NK cells for autoimmunity
Start-ups Showcase (Track 6)
Jiri Eitler, Principal Investigator, Dresden University of Technology
Mar 1014:25
Conference pass
Cell therapy manufacturing transitioning from research to GMP
Cell Therapy Manufacturing (Track 10)
Owen Bain, Director/Qualified Person, Cell & Vector Innovation Centre, Royal Free London NHS Foundation Trust
Mar 1014:25
Conference pass
Engineering Chimeric Antigen Receptor (CAR) T Cells with Novel Costimulatory Domains
Gene Modified Cell Therapy (Track 8)
Ali Roghanian, Professor in Cancer Immunotherapy, University of Southampton
Mar 1014:25
Conference pass
Evolving gene editing for in-born errors of immunity
Gene Editing (Track 5)
Giorgia Santilli, Associate Professor in Gene Therapy, UCL Great Ormond Street Institute of Child Health
Mar 1014:25
Conference pass
Formulation and delivery of new modalities
Viral Vector Manufacturing (Track 9)
Mar 1014:25
Conference pass
Lipid nano particle biodistribution for gene therapy
Gene Therapy (Track 7)
Nagy Habib, Professor of Surgery, Imperial College London
Mar 1014:25
Conference pass
Targeted delivery of advanced therapies and other medicinal payloads
Innovation (Track 2)
Ricardo Baptista, Chief Technology Officer, SmartCella
Mar 1014:25
Conference pass
Treg cells in the clinic: Developing a cell therapy in autoimmunity
Cell Therapy (Track 3)
Piotr Trzonkowski, CEO, PolTREG
Mar 1014:25
Conference pass
What does the Biotech Act mean for the cell and gene community?
Regulation (Track 1)
Andrew Roddam, Founder & Principal, Cibola Life Sciences Ltd
Mar 1014:45
Conference pass
Clinical Potential of MSC-EVs and Translational Challenges
Innovation (Track 2)
Bernd Giebel, Professor, University Hospital Essen
Mar 1014:45
Conference pass
Combinatorial iNKT cell-based immunotherapy for blood cancers
Gene Modified Cell Therapy (Track 8)
Anastasios Karadimitris, Professor, Langmuir Chair in Haematology and Consultant Haematologist, Imperial College London
Mar 1014:45
Conference pass
Gene therapy for infantile parkinsonism
Gene Therapy (Track 7)
Hester Chu, Research Assistant, Neurodegenerative Diseases, UCL
Mar 1014:45
Conference pass
Lessons learned from academic CAR-T manufacturing and process robustness
Cell Therapy Manufacturing (Track 10)
Mar 1014:45
Conference pass
Off-the-shelf iNKT cell therapy
Cell Therapy (Track 3)
Salah Mansour, Professor, University of Southampton
Mar 1014:45
Conference pass
Overcoming challenges of platform technology qualification
Regulation (Track 1)
David Morrow, Scientific Lead for Advanced Therapies, EATRIS
Mar 1014:45
Conference pass
Reprogramming T cell therapies
Gene Editing (Track 5)
Laurie Menger, Advanced T-cell Therapy group leader, Gustave Roussy/INSERM
Mar 1014:45
Conference pass
Tech transfer for AAV manufacturing
Viral Vector Manufacturing (Track 9)
Gaurav Bhavsar, Technical Director GTVF, Gene Therapy Vector Facility, Kings College London
Mar 1014:45
Conference pass
The use of CAR-T reg to treat chronic inflammatory disease
Start-ups Showcase (Track 6)
Sophie Blondel, Co-founder & CEO, Foxbio
Mar 1014:45
Conference pass
Understanding the link between pre-clinical development and GMP manufacturing of ATMP
Pre-Clinical & Clinical (Track 4)
Alessandra Magnani, Head of the advanced therapies and immunotherapy platform, Hospital Sant Joan de Déu Barcelona
Mar 1015:05
Conference pass
Advances in Manufacturing Strategies for Next-Generation Cell Therapies
Cell Therapy Manufacturing (Track 10)
Mar 1015:05
Conference pass
Developing a cell therapy program in Latin America: The Mexican model
Gene Modified Cell Therapy (Track 8)
Alejandro Madrigal, OBE FMedSci, Professor of Haematology, UCL Cancer Institute
Mar 1015:05
Conference pass
Development of a bicistronic dual pathway gene therapy platform to treat AMD: Focus on IKAR-001 for geographic atrophy
Start-ups Showcase (Track 6)
Katie Binley, Chief Scientific Officer, ikarovec
Mar 1015:05
Conference pass
Ex vivo and in vivo gene silencing for programmable therapeutic development
Gene Editing (Track 5)
Tom Payne, Chief Operating Officer, Laverock Therapeutics
Mar 1015:05
Conference pass
Exploring the regulatory challenges for in vivo gene therapies
Regulation (Track 1)
Shirley Bartido, Principal Consultant, CELLiCONsultant
Mar 1015:05
Conference pass
Fireside Chat: Building the workforce of the future to support ATMP development in the UK
Gene Therapy (Track 7)
Moderator: Anji Miller, Skills Lead, Innovation Hubs for Gene Therapies/Programme Director, Translational Skills, LifeArc
Janine Kirby, Professor, University of Sheffield
Mar 1015:05
Conference pass
First in-human clinical trial of allogenic lab grown red blood cells
Cell Therapy (Track 3)
Ash Toye, Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics, University of Bristol
Mar 1015:05
Conference pass
Lessons learned on delivering cell therapy trials in non-oncology indications
Pre-Clinical & Clinical (Track 4)
Ben Parker, Professor of Rheumatology and Director, NIHR Manchester Clinical Research Facility
Mar 1015:05
Conference pass
Manufacturing lenti viral vector as drug product
Viral Vector Manufacturing (Track 9)
Adelina Dan, Senior MSAT Scientist, GTVF, King's College London
Mar 1015:05
Conference pass
Stem cell derived extracellular vesicles as a substitute for cell therapy
Innovation (Track 2)
Mar 1015:55
Conference pass
Chair’s Remarks: Alessandra Magnani, Head of the advanced therapies and immunotherapy platform, Hospital Sant Joan de Déu
Pre-Clinical & Clinical (Track 4)
Alessandra Magnani, Head of the advanced therapies and immunotherapy platform, Hospital Sant Joan de Déu Barcelona
Mar 1015:55
Conference pass
Chair’s Remarks: Ash Toye, Professor of Cell Biology, University of Bristol, Co-founder, Scarlet Therapeutics
Cell Therapy (Track 3)
Ash Toye, Professor of Cell Biology, University of Bristol & Co-founder, Scarlet Therapeutics, University of Bristol
Mar 1015:55
Conference pass
Chair’s Remarks: Darius Widera, Professor of Stem Cell Biology and Regenerative Medicine, University of Reading
Innovation (Track 2)
Mar 1015:55
Conference pass
Chair’s Remarks: David Peritt, Chief Scientific Officer, Lupagen
Gene Modified Cell Therapy (Track 8)
David Peritt, Chief Scientific Officer, Lupagen
Mar 1015:55
Conference pass
Chair’s Remarks: Katie Binley, Chief Scientific Officer, ikarovec
Start-ups Showcase (Track 6)
Katie Binley, Chief Scientific Officer, ikarovec
Mar 1015:55
Conference pass
Chair’s Remarks: Michael Aigner, Head of Manufacturing / QP, University Hospital Erlangen
Cell Therapy Manufacturing (Track 10)
Mar 1015:55
Conference pass
Chair’s Remarks: Olivier Gerrit de Jong, Assistant Professor, Utrecht University
Gene Editing (Track 5)
Olivier Gerrit de Jong, Assistant Professor, Utrecht University
Mar 1015:55
Conference pass
Chair’s Remarks: Pedro Silva Couto, Lecturer, University of Bath
Viral Vector Manufacturing (Track 9)
Pedro Silva Couto, Lecturer, University of Bath
Mar 1015:55
Conference pass
Chair’s Remarks: Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Regulation (Track 1)
Vicki Coutinho, Managing Director & Consultant, Geni Consulting
Mar 1015:55
Conference pass
Chair’s Remarks: Victor Hernandez, CSO, Axovia Therapeutics Ltd
Gene Therapy (Track 7)
Victor Hernandez, CSO, Axovia Therapeutics
Mar 1016:00
Conference pass
A modular strategy for extracellular vesicle-mediated CRISPR-Cas9 delivery through aptamer-based loading and UV-activated cargo release
Gene Editing (Track 5)
Olivier Gerrit de Jong, Assistant Professor, Utrecht University
Mar 1016:00
Conference pass
CARKey: A multi-specific CAR platform for overcoming solid tumour antigen heterogeneity
Start-ups Showcase (Track 6)
John Bridgeman, CSO, ImmunoKey
Mar 1016:00
Conference pass
Developing a regulatory strategy with the end in mind guided by the target development profile
Regulation (Track 1)
Kathryn Parsley, SVP, Regulatory Affairs and Product Development Executive, Complement Therapeutics
Mar 1016:00
Conference pass
Developing a retinol cell therapy: Moving from bench to manufacturing
Cell Therapy Manufacturing (Track 10)
Natalie Francis, Head of Process Development, King's College London
Mar 1016:00
Conference pass
Hydrogel-supported manufacture of MSC-derived EVs
Innovation (Track 2)
Oscar Garcia, Postdoctoral Fellow, BOKU University
Mar 1016:00
Conference pass
Making CAR-T cells efficacious for solid tumours
Gene Modified Cell Therapy (Track 8)
Jun Ishihara, Associate Professor, Imperial College London
Mar 1016:00
Conference pass
Novel muscle tropic viral vectors: Design and manufacturing
Viral Vector Manufacturing (Track 9)
Angela Columbano, Head Business Development and Partnership, Genethon
Mar 1016:00
Conference pass
Routes of administration for CNS hypothalamic disorders
Gene Therapy (Track 7)
Victor Hernandez, CSO, Axovia Therapeutics
Mar 1016:00
Conference pass
UK stem cell network: Leveraging scientific communities in the UK
Cell Therapy (Track 3)
Lyn Healy, Visiting Scientist, King's College London
Mar 1016:00
Conference pass
Using lipid systems biology towards diagnostic and therapeutic gain
Pre-Clinical & Clinical (Track 4)
Sheba Jarvis, Consultant Endocrinology, Imperial College London
Mar 1016:20
Conference pass
AAV gene therapies: Solving the challenge of neutralising antibodies
Gene Therapy (Track 7)
George Frodsham, Founder & CEO, MediSieve Limited
Mar 1016:20
Conference pass
Designing a gene therapy trial for rare disease
Pre-Clinical & Clinical (Track 4)
Mar 1016:20
Conference pass
Enabling LNP-DNA delivery to target peripheral nerve diseases
Start-ups Showcase (Track 6)
Gonzalo Fernández-Miranda, CEO, CureAge Therapeutics
Mar 1016:20
Conference pass
Gene editing for neuromuscular conditions
Gene Editing (Track 5)
Alberto Malerba, Senior Lecturer, Gene Therapy, The Royal Veterinary College
Mar 1016:20
Conference pass
Hospital system readiness for the delivery of advanced therapies: Bottlenecks and opportunities
Cell Therapy (Track 3)
Christian Chabannon, Professor of Medicine in Cell Biology at Aix-Marseille Université. Medical Director & QP, Institut Paoli-Calmettes (IPC)
Mar 1016:20
Conference pass
Modified cell therapies to overcome solid tumours
Gene Modified Cell Therapy (Track 8)
Jonathan Sumner, Associate Principal Scientist, Astrazeneca
Mar 1016:20
Conference pass
Scaling 3D culture in physiological conditions to support manufacturing
Cell Therapy Manufacturing (Track 10)
Cornelia Kasper, Head of Institute for Cell and Tissue Culture Technologies, University Of Natural Resources And Life Sciences Vienna
Mar 1016:20
Conference pass
Strategic Integration of Good AI Practice and Regulatory Flexibility to expedite cell and gene therapy development
Regulation (Track 1)
Anna Koptina, CEO, Exellerium
Mar 1016:20
Conference pass
Therapeutic lab grown red blood cells for metabolic disease
Innovation (Track 2)
Marjolein Meinders, Co-Founder, Scarlet Therapeutics
Mar 1016:20
Conference pass
Towards a digital twin for lentiviral vector chromatography
Viral Vector Manufacturing (Track 9)
George Pamenter, Research Fellow, UCL
last published: 07/Sep/26 15:47 GMT
Get Involved with Advanced Therapies Congress
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events